Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.52 |
| ▸ | HTR3B | O95264 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | BPTF | Q12830 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | KHK | P50053 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27362287 | 0.98 | ADRB1 (0.50) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL28837016 | 0.84 | ADRB1 (0.56) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL15378488 | 0.79 | KHK (0.57) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4246315 | 0.79 | KHK (0.57) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4246310 | 0.79 | KHK (0.57) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL10318584 | 0.79 | USP2 (0.48) | ADRB1NOTUMUSP2KDM4EALDH1A1 | |
| SCHEMBL2293331 | 0.78 | NOTUM (0.48) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL30889351 | 0.78 | ADRB1 (0.52) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4423739 | 0.78 | ADRB1 (0.52) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL15819287 | 0.78 | KHK (0.56) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 930 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221438-B2 | Continuous process for the preparation of trazodone | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2025-02-11 | — | — | US | claimed |
| US-20240252535-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | YZTHERAPEUTIC PERFORMANCE LTD. (IL) | 2024-08-01 | — | — | US | claimed |
| US-20240245693-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-25 | — | — | US | claimed |
| EP-4340940-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | The Regents of University of California (US) | 2024-03-27 | — | — | EP | claimed |
| WO-2023218251-A1 | NOVEL DEUTERIUM-ENRICHED NEFAZODONE ANALOGUES AND METHOD FOR PREPARING THEREOF | CLEARSYNTH LABS LIMIED (IN) | 2023-11-16 | — | — | WO | claimed |
| CN-116640418-B | Electrochromic display device and preparation method thereof | 苏州欧谱科显示科技有限公司 | 2023-11-03 | — | — | CN | claimed |
| CN-116640418-A | Electrochromic material and preparation method and application thereof | 苏州欧谱科显示科技有限公司 | 2023-08-25 | — | — | CN | claimed |
| EP-4208177-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | Yztherapeutic Performance Ltd. (IL) | 2023-07-12 | — | — | EP | claimed |
| CN-111886235-B | Continuous process for preparing trazodone | 方济各安吉利克化学联合股份有限公司 | 2023-06-30 | — | — | CN | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| WO-2005107473-A2 | TREATING DIGESTIVE TRACT CONDITIONS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2005-11-17 | — | — | WO | claimed |
| US-6946141-B2 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS, INC. (US) | 2005-09-20 | — | — | US | claimed |
| EP-1389115-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-02-18 | — | — | EP | claimed |
| US-6495154-B1 | ADMINISTERING ANTIDEPRESSANTS, ADRENERGIC STIMULANTS, SEROTONIN AGONISTS AND ANTAGONISTS AS THERAPEUTIC AGENTS FOR SEXUAL DISORDERS | VIVUS INC. | 2002-12-17 | — | — | US | claimed |
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS LLC (F/K/A VIVUS, INC.) | 2002-10-31 | — | — | US | claimed |
| WO-2002041883-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| US-20010008896-A1 | Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation | SMITH WILLIAM L (US) | 2001-07-19 | — | — | US | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| US-5788986-A | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression using R enantiomers, S enantiomers, and racemic mixtures of selective serotonin reuptake inhibitor compounds or their active metabolites | TRUSTEES OF TUFTS COLLEGE (US) | 1998-08-04 | — | — | US | claimed |
| US-5504086-A | MAXIMIZING ANTIANXIETY, ANTICONVULSANT AND/OR HYPNOTIC EFFECTS; HUMAN CENTRAL NERVOUS SYSTEM; SIDE EFFECT REDUCTION | ELLINWOOD JR EVERETT H (US) | 1996-04-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221438-B2 | Continuous process for the preparation of trazodone | CYP3A5, OPRK1, OPRD1 | ADRB1 304/4885HTR3E 28/4885HTR3B 41/4885 |
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | HTR5A, HTR1A, MAOA | ADRB1 630/4885HTR3E 49/4885HTR3B 39/4885 |
| US-20240245693-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | ADORA2B, ADORA2A, ANXA3 | ADRB1 266/4885HTR3E 1872/4885HTR3B 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.